Pancreatic Cancer Survival in Elderly Patients Treated With Chemotherapy

Objectives Pancreatic cancer is a lethal disease mostly affecting elderly people. Clinical trials on treatment contain disproportionately fewer elderly patients compared with everyday practice. This retrospective study evaluates differences in the rates of chemotherapy delivered and associated survival in different age groups. Methods Data were collected from the Cancer Information Resource Files on patients diagnosed with pancreatic cancer from 1993 to 2008. Patients were divided into 3 age groups, namely, A with younger than 50 years, B with 50 to 70 years old, and C with older than 70 years. Results Complete data were available on 16,694 patients. Forty-four percent were in group C. Chemotherapy was given to 38% of patients in group C versus 69% of patients in group A. A multivariate analysis revealed a similar chemotherapy benefit in all groups, as follows: group C (hazard ratio [HR], 0.51), group A (HR, 0.74), and group B (HR, 0.55). Conclusions We found that elderly patients with pancreatic cancer receive treatment less frequently compared with younger patients. However, elderly patients receiving chemotherapy derive similar benefits. Randomized clinical trials are needed to evaluate pancreatic cancer treatment in the elderly patients, particularly given the increasing occurrence of pancreatic cancer in later life.

[1]  H. Cohen,et al.  Never too old? Age should not be a barrier to enrollment in cancer clinical trials. , 2005, The oncologist.

[2]  J. Samet,et al.  Choice of cancer therapy varies with age of patient. , 1986, JAMA.

[3]  H. El‐Serag,et al.  The epidemiology of pancreatic cancer in the United States: changes below the surface , 2006, Alimentary pharmacology & therapeutics.

[4]  J. Niederhuber,et al.  The national cancer data base report on pancreatic cancer , 1995, Cancer.

[5]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[6]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[7]  Z. Nugent,et al.  Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba. , 2011, Current oncology.

[8]  Vincent Mor,et al.  Relationship Between Age at Diagnosis and Treatments , 1985, Journal of the American Geriatrics Society.

[9]  M. Extermann,et al.  Cancer chemotherapy in the older patient , 1997, Cancer.

[10]  M. Saif,et al.  Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. , 2009, JOP : Journal of the pancreas.

[11]  A. Ardizzoni,et al.  Gemcitabine: Safety profile and efficacy in non-small cell lung cancer unaffected by age , 1997, Aging.

[12]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[13]  J. Furuse,et al.  Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. , 2007, Japanese journal of clinical oncology.

[14]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[15]  Lodovico Balducci,et al.  Cancer and age: general considerations. , 2012, Clinics in geriatric medicine.

[16]  Lodovico Balducci,et al.  Aging, frailty, and chemotherapy. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[17]  I. Aldoss,et al.  Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer — A Veterans Affairs Cancer Registry analysis ☆ , 2011 .